Clinical Trial Update: A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety study of the dapivirine vaginal gel for HIV prevention in South Africa has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dapivirine vaginal gel (TMC120) (dapivirine)

Snippet

Sponsor: International Partnership for Microbicides, Inc. | Conditions: HIV Infections | Phase 1, Phase 2 | Status: WITHDRAWN